Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) reached a new 52-week high during trading on Monday . The company traded as high as $48.87 and last traded at $47.99, with a volume of 321456 shares traded. The stock had previously closed at $47.75.
Gemini Therapeutics Trading Up 0.7 %
The stock has a fifty day moving average of $48.35 and a two-hundred day moving average of $41.10. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -47.99 and a beta of -0.12.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Articles
- Five stocks we like better than Gemini Therapeutics
- How to Invest in the FAANG Stocks
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Stock Market Upgrades: What Are They?
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
